Efficacy and Safety on the Use of Bisphosphonates in Paediatrics

Centre Hospitalier Universitaire de Nīmes99 enrolled

Overview

The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bone Fragile Bisphosphonate-Associated Osteonecrosis Children Adverse Events

Interventions

No intervention, observational studyOTHER

No intervention, observational study

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * be under 18 years of age * have been treated by intravenous bisphosphonates for primary or secondary osteoporosis Exclusion Criteria: * be over 18 years of age

Locations (1)

CHUNimes

Nîmes, France

Outcomes

Primary Outcomes

fracture rates

(numbers)

Time frame: 2 years

bone mineral density

(Z-score)

Time frame: 2 years

pain frequency

(never, occasional, regular)

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.